Inflammasome — a new look at the therapy of cardiovascular diseases. Part II
https://doi.org/10.15829/1560-4071-2025-6058
EDN: DKFMPF
Abstract
The role of inflammasomes in cardiovascular diseases has not been sufficiently studied at present. However, there are a number of recent studies showing the participation of these multiprotein complexes in the development and progression of cardiovascular diseases. Thus, in atrial fibrillation, the inflammasome triggering helps to reduce the duration and refractivity of the atrial action potential, induction of early and/or delayed afterdepolarization, which maintains ectopic activity. In heart failure, the triggering of inflammasome cascade initiates and maintains chronic inflammation, leading to cardiac remodeling and fibrosis. In coronary artery disease, inflammasome activation maintains ischemia and increases the necrosis area. Inflammatory reactions in pericarditis and myocarditis also do not occur without the participation of this multiprotein complex. In these pathologies, inflammasome inhibition helps to improve clinical symptoms and normalize the cardiac function. Therefore, inflammasome inhibitor agents can become a promising method of therapy in the above diseases.
Keywords
inflammasome,
atrial fibrillation,
heart failure,
coronary artery disease,
pericarditis,
myocarditis
Supporting agencies: Relationships and Activities. The study was financially supported by the Ministry of Science and Higher Education of the Russian Federation (agreement № 075-15-2022-301 dated April 20, 2022)
About the Authors
A. A. Rubinstein
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
A. A. Khodot
Almazov National Medical Research Center
Competing Interests:
St. Petersburg
Competing Interests:
none
P. V. Tirikova
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
A. S. Golovkin
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
I. V. Kudryavtsev
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
E. V. Shlyakhto
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg
Competing Interests:
none
References
1. Yao C, Veleva T, Scott L, et al. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018;138(20):2227-42. doi:10.1161/CIRCULATIONAHA.118.035202.
2. Li L, Coarfa C, Yuan Y, et al. Fibroblast-specific inflammasome activation predisposes to atrial fibrillation. BioRxiv Prepr Serv Biol. 2023:2023.05.18.541326. doi:10.1101/2023.05.18.541326.
3. Heijman J, Muna AP, Veleva T, et al. Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation. Circ Res. 2020;127(8):1036-55. doi:10.1161/CIRCRESAHA.120.316710.
4. Brundel BJJM, Ai X, Hills MT, et al. Atrial fibrillation. Nat Rev Dis Primer. 2022;8(1):21. doi:10.1038/s41572-022-00347-9.
5. Gawałko M, Saljic A, Li N, et al. Adiposity-associated atrial fibrillation: molecular determinants, mechanisms, and clinical significance. Cardiovasc Res. 2023;119(3):614-30. doi:10.1093/cvr/cvac093.
6. Scott L, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2019;287:195-200. doi:10.1016/j.ijcard.2018.10.020.
7. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2010;12(12):1713-8. doi:10.1093/europace/euq321.
8. Pappritz K, Lin J, El-Shafeey M, et al. Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. ESC Heart Fail. 2022;9(2):925-41. doi:10.1002/ehf2.13845.
9. Ajoolabady A, Nattel S, Lip GYH, et al. Inflammasome Signaling in Atrial Fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(23):2349-66. doi:10.1016/j.jacc.2022.03.379.
10. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1): 104-32. doi:10.1016/j.jacc.2019.01.011.
11. Onódi Z, Ruppert M, Kucsera D, et al. AIM2-driven inflammasome activation in heart failure. Cardiovasc Res. 2021;117(13):2639-51. doi:10.1093/cvr/cvab202.
12. Bracey NA, Gershkovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem. 2014;289(28):19571-84. doi:10.1074/jbc.M114.550624.
13. Cheng X, Zhao H, Wen X, et al. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sci. 2023;333:122185. doi:10.1016/j.lfs.2023.122185.
14. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964-71. doi:10.1016/s0735-1097(96)00268-9.
15. Wang Y, Li Y, Zhang W, et al. NLRP3 Inflammasome: a Novel Insight into Heart Failure. J Cardiovasc Transl Res. 2023;16(1):166-76. doi:10.1007/s12265-022-10286-1.
16. Buckley LF, Carbone S, Trankle CR, et al. Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical Trials. J Cardiovasc Pharmacol. 2018;72(1):68-70. doi:10.1097/FJC.0000000000000591.
17. Trankle CR, Canada JM, Cei L, et al. Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. Am J Cardiol. 2018;122(8):1366-70. doi:10.1016/j.amjcard.2018.07.002.
18. Everett BM, Cornel JH, Lainscak M, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019;139(10):1289-99. doi:10.1161/CIRCULATIONAHA.118.038010.
19. Wohlford GF, Van Tassell BW, Billingsley HE, et al. Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. J Cardiovasc Pharmacol. 2020;77(1):49-60. doi:10.1097/FJC.0000000000000931.
20. Xu H, Yu W, Sun S, et al. TAX1BP1 protects against myocardial infarction-associated cardiac anomalies through inhibition of inflammasomes in a RNF34/MAVS/NLRP3-dependent manner. Sci Bull. 2021;66(16):1669-83. doi:10.1016/j.scib.2021.01.030.
21. Ryabov VV, Gombozhapova AE, Samoilova YuO, et al. NLRP3 inflammasome in the pathogenesis of acute myocardial infarction: a cardiologist's view. Russian Journal of Cardiology. 2024;29(4):5649. (In Russ.) Рябов В. В., Гомбожапова А. Э., Самойлова Ю. О. и др. NLRP3 инфламмасома в патогенезе острого инфаркта миокарда: взгляд кардиолога. Российский кардиологический журнал. 2024;29(4):5649. doi:10.15829/1560-4071-2024-5649.
22. Rajamäki K, Mäyränpää MI, Risco A, et al. p38δ MAPK: A Novel Regulator of NLRP3 Inflammasome Activation With Increased Expression in Coronary Atherogenesis. Arterioscler Thromb Vasc Biol. 2016;36(9):1937-46. doi:10.1161/ATVBAHA.115.307312.
23. Nordeng J, Schandiz H, Solheim S, et al. The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI. Mediators Inflamm. 2021;2021:5525917. doi:10.1155/2021/5525917.
24. Zhu J, Wu S, Hu S, et al. NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. Mol Med Rep. 2019;20(2):1826-36. doi:10.3892/mmr.2019.10382.
25. Akosile W, Voisey J, Lawford B, et al. NLRP3 is associated with coronary artery disease in Vietnam veterans. Gene. 2020;725:144163. doi:10.1016/j.gene.2019.144163.
26. Afrasyab A, Qu P, Zhao Y, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart Vessels. 2016;31(8): 1218-29. doi:10.1007/s00380-015-0723-8.
27. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-47. doi:10.1056/NEJMoa2021372.
28. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-505. doi:10.1056/NEJMoa1912388.
29. Tucker B, Kurup R, Barraclough J, et al. Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. Clin Ther. 2019;41(10):2172-81. doi:10.1016/j.clinthera.2019.07.015.
30. Mewton N, Roubille F, Bresson D, et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021;144(11):859-69. doi:10.1161/CIRCULATIONAHA.121.056177.
31. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-31. doi:10.1056/NEJMoa1707914.
32. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394-400. doi:10.1016/j.amjcard.2013.01.287.
33. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105(10):1371-7.e1. doi:10.1016/j.amjcard.2009.12.059.
34. Mauro AG, Bonaventura A, Vecchié A, et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC Basic Transl Sci. 2021;6(2): 137-50. doi:10.1016/j.jacbts.2020.11.016.
35. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet Lond Engl. 2014;383(9936):2232-7. doi:10.1016/S0140-6736(13)62709-9.
36. Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27(9):956-64. doi:10.1177/2047487319879534.
37. Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-12. doi:10.1001/jama.2016.15826.
38. Collini V, Andreis A, De Biasio M, et al. Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis. Open Heart. 2024;11(1):e002599. doi:10.1136/openhrt-2023-002599.
39. Klein AL, Imazio M, Cremer P, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021;384(1):31-41. doi:10.1056/NEJMoa2027892.
40. Toldo S, Kannan H, Bussani R, et al. Formation of the inflammasome in acute myocarditis. Int J Cardiol. 2014;171(3):e119-21. doi:10.1016/j.ijcard.2013.12.137.
41. Han RO, Ray PE, Baughman KL, et al. Detection of interleukin and interleukin-receptor mRNA in human heart by polymerase chain reaction. Biochem Biophys Res Commun. 1991;181(2):520-3. doi:10.1016/0006-291x(91)91219-3.
42. Malandrino D, Bello F, Lopalco G, et al. Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis. Intern Emerg Med. 2024;19(2):583-8. doi:10.1007/s11739-023-03514-2.
43. Kerneis M, Cohen F, Combes A, et al. Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Arch Cardiovasc Dis. 2023;116(10):460-6. doi:10.1016/j.acvd.2023.07.004.
44. Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2018;11(8):e005036. doi:10.1161/CIRCHEARTFAILURE.118.005036.
45. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50. doi:10.1016/j.semarthrit.2015.06.013.
46. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132(15):1395-403. doi:10.1161/CIRCULATIONAHA.115.017611.
47. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193.
48. Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127. doi:10.1038/s41467-020-15983-6.
- In atrial fibrillation, inflammasome activation leads to maintenance of ectopic activity.
- In heart failure, the inflammasome promotes initiation of myocardial remodeling and maintenance of chronic inflammation in the cardiac tissue.
- The inflammasome cascade is triggered by myocarditis and pericarditis, which promotes maintenance of inflammatory reactions.
- Coronary artery disease is accompanied by inflammasome activation in cardiomyocytes, which leads to necrosis progression and, as a consequence, to cardiac dysfunction.
- Therapy aimed at inhibiting the inflammasome is a promising method for treating cardiovascular diseases; however, many drugs have not been studied enough at the moment and cannot be used in routine practice.
Review
For citations:
Rubinstein A.A., Khodot A.A., Tirikova P.V., Golovkin A.S., Kudryavtsev I.V., Shlyakhto E.V. Inflammasome — a new look at the therapy of cardiovascular diseases. Part II. Russian Journal of Cardiology. 2025;30(6S):6058. (In Russ.) https://doi.org/10.15829/1560-4071-2025-6058. EDN: DKFMPF
Views:
304
Email this article 